Utah's AI Prescription Renewal Program: A Pioneering Initiative

Utah has launched a groundbreaking pilot program that allows artificial intelligence (AI) to autonomously renew certain medical prescriptions, marking a first in the United States. This initiative, developed in collaboration with health-tech startup Doctronic, aims to streamline the prescription renewal process for patients with chronic conditions. The program began quietly last month and represents a significant test of public and regulatory trust in AI's role in healthcare.

Politico

The AI system is designed to handle routine prescription renewals without human intervention. Patients in Utah can access the system through a dedicated webpage that verifies their location and retrieves their prescription history. The AI then engages patients with clinical questions similar to those posed by a physician to assess the appropriateness of a refill. If approved, the prescription is sent directly to a pharmacy. The program currently covers 190 commonly prescribed medications, excluding those deemed high-risk, such as pain management and ADHD drugs.

Politico

To ensure safety, human doctors will review the first 250 prescriptions in each medication class to validate the AI's performance. The AI is programmed to escalate cases to a physician if uncertainties arise. Additionally, Doctronic has secured a unique malpractice insurance policy for its AI system, holding it to the same accountability standards as human doctors. Dr. Adam Oskowitz, co-founder of Doctronic, asserts that the AI performs safety checks that human doctors may overlook, claiming it could be "infinitely safer than a human doctor."

Politico

The initiative raises important questions about the regulation of AI in healthcare. Al Carter, CEO of the National Association of Boards of Pharmacy, acknowledges the existing use of AI in prescription fulfillment but emphasizes the need for regulatory clarity. The Food and Drug Administration (FDA) has yet to comment on the program, but its potential authority to regulate AI as a medical device could complicate the initiative's expansion. Former FDA chief counsel Lowell Schiller notes that the agency may defer to state laws, as seen with medical marijuana, but could also enforce compliance if necessary.

Politico

Despite the potential benefits, the program faces criticism from medical professionals. Concerns include the risk of misuse by individuals with substance abuse issues and the possibility of missing critical clinical indicators that a human doctor would typically catch. Doctors' groups warn that delegating prescription authority to AI could introduce new hazards in patient care.

Politico

The success of Utah's pilot program could influence AI policy and healthcare delivery across the United States. Doctronic's leadership is already in discussions with other states, including Texas, Arizona, and Missouri, about expanding the program. The outcome will largely depend on the FDA's regulatory stance and the evolving landscape of AI in medicine.

Politico

• “The AI is actually better than doctors at doing this,” — Dr. Adam Oskowitz, Co-founder, Doctronic

Politico

• “We want it to be done in such a way that people will trust that Utah is looking at this carefully and is not being cavalier about how we granted this regulatory mitigation.” — Busse, State Official

Politico

• “In medicine, there’s always going to be potential issues that patients have,” — Dr. Adam Oskowitz, Co-founder, Doctronic

Politico

• “Now we’re in this weird place where there are devices — maybe you could call them devices — that are purporting to practice medicine,” — Zach Boyd, Director, Utah AI Policy Office

Politico

Utah's initiative represents a significant step in integrating AI into healthcare, balancing innovation with the need for safety and regulatory oversight.

Politico